Meribendan

This classification denotes a cardiotonic agent with the molecular formula C15H14N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4WYD7I9GF4, chemically known as 4,5-dihydro-5-methyl-6-(2-pyrazol-3-yl-5-benzimidazolyl)-3(2h)-pyridazinone but generally known as meribendan, which bears US NIH Compound Identifier 5464106. European Medicines Agency schedules Meribendan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08776MIG. The term MERIBENDAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). MERIBENDAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule meribendan under HS 29331990 and SITC 51571. As of Q4 2014, MERIBENDAN remains the US FDA Preferred Term for this commodity. Meribendan bears US NLM identifiers UMLS ID C0381415 and NCI Concept Code C83936. SMILES: O=C1NN=C(C(C1)C)C1CC2=N/C(=C3/[NH][NH]CC3)N=C2CC1.